John A. Spertus, MD, MPH

home / authors / john-a-spertus-md-mph

Articles

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

June 1st 2022

Expert cardiologists share strategies for educating patients on the treatment and management of hypertrophic cardiomyopathy.

Future Directions for oHCM Treatment

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

June 1st 2022

Drs Steve R. Ommen, Martin S. Maron, Javed Butler, and James Januzzi provide insight on the evolving treatment landscape for obstructive hypertrophic cardiomyopathy.

VALOR-HCM Study in oHCM

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

June 1st 2022

A panel of experts in cardiovascular medicine review the use of mavacamten as seen in the VALOR-HCM study for patients with symptomatic oHCM who are eligible for septal reduction therapy.

Long-Term Data of Mavacamten Use in oHCM

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

June 1st 2022

Martin S. Maron, MD, examines long-term data with mavacamten for oHCM treatment that was presented at ACC 2022.

Health Status With Different HCM Treatments

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

June 1st 2022

Cardiac specialists discuss improvement in health status with different treatments for hypertrophic cardiomyopathy.

EXPLORER-HCM Trial in oHCM

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

June 1st 2022

John A. Spertus, MD, MPH, and Martin S. Maron, MD comment on the role of mavacamten in oHCM as seen in the EXPLORER-HCM trial.

Emerging Therapies for oHCM

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

June 1st 2022

Steve R. Ommen, MD, discusses the use of novel agents in the pipeline for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).

Approaching Treatment Selection for Hypertrophic Cardiomyopathy

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

June 1st 2022

Steve R. Ommen, MD, leads a discussion on factors to consider when choosing treatment for hypertrophic cardiomyopathy (HCM).

Invasive Treatments and Challenges with HCM Treatments

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

May 31st 2022

Experts in cardiology review invasive treatments, challenges with HCM treatments, and how to optimize treatment for patients.

Treatment Approaches for HCM

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

May 31st 2022

Drs Javed Butler, Martin S. Maron, Steve R. Ommen, and James Januzzi provide insight on approaching treatment of HCM with pharmacologic and nonpharmacologic interventions.

AHA/ACC HCM Guidelines and Patient Identification and Management

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

May 31st 2022

Steve R. Ommen, MD; and Martin S. Maron, MD, review the role of AHA/ACC guidelines, imaging techniques, and circulating biomarkers in approaching the diagnosis and treatment of hypertrophic cardiomyopathy.

The Effect of Obstructive Hypertrophic Cardiomyopathy on Health Status

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

May 31st 2022

John A. Spertus, MD, MPH, comments on the effect of oHCM on health status and quality of life for patients.

Symptoms of Hypertrophic Cardiomyopathy

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

May 31st 2022

Drs Steve R. Ommen, Martin S. Maron, John A. Spertus, Javed Butler, and James Januzzi provide insight on the presentation of nonobstructive and obstructive hypertrophic cardiomyopathy.

Role of Genetic Mutations in HCM Pathophysiology

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

May 6th 2022

Steve R. Ommen, MD, leads a review of common mutations seen in hypertrophic cardiomyopathy and the role of biomarkers and genetic testing in HCM.

Overview of Hypertrophic Cardiomyopathy

James Januzzi, MD;Steve R. Ommen, MD;John A. Spertus, MD, MPH;Martin S. Maron, MD;Javed Butler, MD, MPH, MBA

May 6th 2022

Martin S. Maron, MD, discusses the incidence and prevalence of hypertrophic cardiomyopathy and age of disease expression.